CUVL vs RIV Comparison

Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.

Rivernorth Opportunities Fund Inc is a diversified, closed-end management investment company. Its investment objective is total return consisting of capital appreciation and current income. The Fund employs a tactical asset allocation plan focused on closed-end funds (CEFs), exchange-traded funds (ETFs), special purpose acquisition companies (SPACs), and business development companies (BDCs). The majority of its portfolio is invested in closed-end funds (CEFs).